Issues

Analyses of longitudinal peripheral biomarkers and baseline tumor tissue from JAVELIN Renal 101 provide novel evidence of differential immunomodulatory mechanisms in patients with advanced renal cell carcinoma treated with avelumab plus axitinib versus sunitinib.

A cell-free DNA methylation panel was developed that can quantify tumor fraction and identify neuroendocrine prostate cancer noninvasively, which may improve early detection and treatment of this disease.

The CDK2 inhibitor INX-315 induces cell cycle arrest and therapy-induced senescence, thereby controlling the growth of CCNE1-amplified cancers and CDK4/6 inhibitor-resistant breast cancers, which together supports future clinical development.

Targeting the DNA/RNA helicase DHX9 induces the accumulation of double-stranded RNA and R-loops in small cell lung cancer cells, enhancing immunotherapy response and opening new therapeutic opportunities in immunologically ‘cold’ tumors.

Passenger gene co-amplification is a largely overlooked but common event in many cancers that creates tumor-specific, therapeutically actionable dependencies with the potential to expand target discovery in oncology.

Deep learning was implemented to integrate cancer-associated genetic alterations with known protein-protein interaction networks and create predictive models of response to replication stress-inducing agents.

A metabolic relationship was demonstrated between tumor-associated alveolar macrophages and transformed epithelium that sustains oncogenic signaling and tumor proliferation, revealing potential immuno-metabolic targets for immunotherapy-resistant lung tumors.